Patent ID: 7612063

Claim:
A method for treating or ameliorating a cell proliferative disorder, comprising administering to a subject in need thereof an effective amount of a compound of formula 1 or a pharmaceutically acceptable salt or a pharmaceutical composition thereof, wherein: V is H, halo, NR 1 R 2 , NH 2 , or NR 1 —(CR 1 2 ) n —NR 3 R 4 ; A is H, fluoro, or NR 1 2 ; Z is O; U is selected from the group consisting of NR 1 —(CR 1 2 ) n —NR 3 R 4 and NR 1 R; X is OR 2 , NR 1 R 2 , halo, azido, or SR 2 ; n is 1-6; R is an optionally substituted 5-14 membered heterocyclic ring containing one or more N, O or S; or R is a C 1-10 alkyl or C 2-10 alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with an optionally substituted carbocyclic or heterocyclic ring; R 1 and R 3 are independently H or an optionally substituted C 1-6 alkyl, said alkyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S; R 2 and R 4 are independently H or a C 1-10 alkyl or C 2-10 alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with an optionally substituted carbocyclic or heterocyclic ring; and wherein said C 1-10 alkyl may be optionally substituted by one or more OH, C 1-6 alkoxy, amino, amido, halo, ═O, aryl or heterocyclic groups; or R 2 is an optionally substituted heterocyclic ring, aryl or heteroaryl; wherein R 1 and R 2 together with N in NR 1 R 2 , and/or R 3 and R 4 together with N in NR 3 R 4 , and/or R 1 and R together with N in NR 1 R may independently form an optionally substituted 5-6 membered ring containing N, and optionally O or S; W is selected from the group consisting of wherein Q, Q 1 , Q 2 , and Q 3 are independently CH or N; Y is independently O, CH, ═O or NR 1 ; and R 5 is a substituent at any position on the fused ring; and is H, OR 2 , C 1-6 alkyl, or C 2-6 alkenyl, each optionally substituted by halo, ═O or one or more heteroatoms; or R 5 is an inorganic substituent; or two adjacent R 5 are linked to obtain a 5-6 membered optionally substituted carbocyclic or heterocyclic ring, optionally fused to an additional optionally substituted carbocyclic or heterocyclic ring; provided that U is not morpholinyl or 2,4-difluoroaniline when X is F or pyrrolidinyl; A is F; and W is phenylene; wherein said cell proliferative disorder is a cancer selected from colorectal cancer, breast cancer, lung cancer, liver cancer, pancreatic cancer, prostate cancer, brain cancer, skin cancer, renal cancer, ovarian cancer, cervical cancer, leukemia, and lymphoma; thereby treating or ameliorating said cell-proliferative disorder.